UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma

Annals of oncology, 2018-10, Vol.29, p.viii23-viii23

2018

Volltextzugriff (PDF)

Tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer

Annals of oncology, 2018-10, Vol.29, p.viii645-viii645

2018

Volltextzugriff (PDF)

Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)

Opukholi golovy i shei, 2018-11, Vol.8 (3), p.53-60

2018

Volltextzugriff (PDF)

Влияние прерывания терапии ленватинибом на общую эффективность лечения у пациентов с радиойодрезистентным дифференцированным раком щитовидной железы в исследовании III фазы

Opukholi golovy i shei, 2019-04, Vol.9 (1), p.38-50

2019

Volltextzugriff (PDF)

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors

Annals of oncology, 2016-10, Vol.27, p.vi267-vi267

2016

Volltextzugriff (PDF)

Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung

Annals of oncology, 2016-10, Vol.27, p.vi417-vi417

2016

Volltextzugriff (PDF)

1862PDImpact of lung metastasis on overall survival (OS) in the phase III SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Annals of oncology, 2018-10, Vol.29, p.viii17-viii18

2018

Volltextzugriff (PDF)

1819OTumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

76PCorrelative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1187PDPhase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Responses in specific metastases following treatment with lenvatinib (LN): Results from the phase 3 SELECT trial

Annals of oncology, 2016-10, Vol.27, p.vi332-vi332

2016

Volltextzugriff (PDF)

59PDFinal analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

The relationship between age and survival outcomes for eribulin in metastatic breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1060-1060

2011

Volltextzugriff (PDF)

Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P3-P3-13-04

2013

Volltextzugriff (PDF)

Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.S6-S6-6

2012

Volltextzugriff (PDF)

Abstract P3-13-03: A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P3-P3-13-03

2013

Volltextzugriff (PDF)

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

Journal of clinical oncology, 2020-04, Vol.38 (11), p.1154-1163

2020

Volltextzugriff (PDF)

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

The New England journal of medicine, 2021-04, Vol.384 (14), p.1289-1300

2021

Volltextzugriff (PDF)

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

The New England journal of medicine, 2021-04, Vol.384 (14), p.1289-1300

2021

Volltextzugriff (PDF)

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

Clinical cancer research, 2021-09, Vol.27 (17), p.4848-4858

2021

Volltextzugriff (PDF)

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial

Gynecologic oncology, 2020-10, Vol.159, p.6-7

2020

Volltextzugriff (PDF)

Eine unverblindete, randomisierte Phase III-Studie zum Vergleich von Eribulin versus Capecitabin bei Patientinnen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs nach Vorbehandlung mit Anthrazyklinen und Taxanen: Subgruppen-Analysen

Senologie (Stuttgart), 2013, Vol.10 (2)

2013

Volltextzugriff (PDF)

Lebensqualität von Patientinnen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs nach Vorbehandlung mit Anthrazyklinen und Taxanen unter der Behandlung mit Eribulin oder Capecitabin: eine randomisierte, unverblindete Phase III-Studie

Senologie (Stuttgart), 2013, Vol.10 (2)

2013

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(23)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma

Tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer

Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors

Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung

1862PDImpact of lung metastasis on overall survival (OS) in the phase III SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

1819OTumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer

76PCorrelative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma

1187PDPhase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis

994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)

Responses in specific metastases following treatment with lenvatinib (LN): Results from the phase 3 SELECT trial

59PDFinal analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

The relationship between age and survival outcomes for eribulin in metastatic breast cancer

Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301

Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

Abstract P3-13-03: A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial

Eine unverblindete, randomisierte Phase III-Studie zum Vergleich von Eribulin versus Capecitabin bei Patientinnen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs nach Vorbehandlung mit Anthrazyklinen und Taxanen: Subgruppen-Analysen

Lebensqualität von Patientinnen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs nach Vorbehandlung mit Anthrazyklinen und Taxanen unter der Behandlung mit Eribulin oder Capecitabin: eine randomisierte, unverblindete Phase III-Studie

Suchergebnisse filtern